Fushine(SZ:300497) Xin Lang Zheng Quan·2025-10-31 10:36Core Viewpoint - Fuxiang Pharmaceutical, established in 2002 and listed in 2015, is a leader in the domestic specialty antibacterial raw material drug sector, possessing a full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Fuxiang Pharmaceutical reported revenue of 769 million yuan, ranking 21st among 47 peers, while the industry leader, Puluo Pharmaceutical, achieved revenue of 7.764 billion yuan [2] - The company's net profit for the same period was -67.6848 million yuan, placing it 43rd in the industry, with the top performer, Zhejiang Pharmaceutical, reporting a net profit of 867 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Fuxiang Pharmaceutical's debt-to-asset ratio was 51.15%, higher than the previous year's 48.65% and above the industry average of 27.75% [3] - The gross profit margin for Q3 2025 was 12.05%, an increase from 9.91% year-on-year, but still below the industry average of 35.38% [3] Group 3: Executive Compensation - The chairman and general manager, Bao Jianhua, received a salary of 1.2525 million yuan in 2024, a slight increase from 1.2491 million yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 7.87% to 20,700, while the average number of circulating A-shares held per shareholder increased by 5.59% to 21,300 [5]